AI-Discovered Peptide BRP Shows Potential for Obesity Treatment with Reduced Side Effects
Introduction
Researchers at Stanford Medicine have identified a naturally occurring molecule, called BRP, which suppresses appetite by acting directly on the brain''s hypothalamus. The discovery, made possible by an artificial intelligence tool, may lead to new obesity treatments that avoid the gastrointestinal side effects associated with current GLP-1 receptor agonist drugs such as Ozempic, Wegovy, and Mounjaro.
Main Body
The molecule BRP is a 12-amino-acid peptide that was found using a custom AI system called Peptide Predictor. This tool scanned about 20,000 human genes and identified 2,683 candidate hormone-like peptides. From these, the Stanford team selected around 100 for testing. BRP proved to be the most effective at reducing weight in obese mice. The mice that received daily injections lost weight, while untreated control mice gained weight. Katrin Svensson, the senior author of the study, has co-founded a company to begin human clinical trials soon. Current weight-loss injections copy the hormone GLP-1, which acts on multiple body systems to suppress appetite. However, their main mechanism involves the hindbrain, which creates feelings of fullness. In many patients, this leads to nausea, vomiting, diarrhea, abdominal pain, and constipation. Giles Yeo, professor of molecular neuroendocrinology at the UK Medical Research Council''s Metabolic Diseases Unit, explained that the hindbrain causes physical effects such as uncomfortable fullness, whereas the hypothalamus works as a hunger sensor that detects when the body needs energy. BRP appears to act only on the hypothalamus, potentially reducing appetite without causing the unpleasant fullness that leads to nausea. Furthermore, animal trials showed that BRP promoted fat loss without muscle loss, a side effect sometimes seen with GLP-1 mimics. Randy J. Seeley, professor of surgery at the University of Michigan, commented positively on the scale of the peptide screening but warned that success in animal models does not guarantee that the drug will work or be safe in humans. He noted that obesity is a chronic condition requiring long-term treatment, so any new drug must be very safe for prolonged use. GLP-1-based drugs, which are modified versions of natural hormones engineered to last longer in the body, also offer cardiovascular benefits beyond weight loss. BRP could similarly be changed to have extended activity. Yeo emphasized that additional treatment options are very important given the global obesity crisis, with about one billion people affected and obesity now causing more deaths than famine. He stated that having a variety of tools increases the chance that patients will find a sustainable treatment plan and maintain weight loss.
Conclusion
The discovery of BRP could be an important step forward in obesity treatment, offering a mechanism that may avoid the nausea associated with current GLP-1 agonists. However, its clinical usefulness depends on successful human trials and long-term safety assessments. Even if approved, BRP is expected to complement rather than replace existing treatments, as GLP-1 drugs provide additional health benefits. The use of AI to identify new peptides is a methodological innovation that could speed up future drug development.